Search All Tech Briefings


Search technology briefings produced by NIHR Innovation Observatory. These are short reports on new or repurposed medicines that we have already sent to our stakeholders. Only those technologies (medicines) that are within the scope of our stakeholders will have a technology briefing available.  Search our technology briefings by intervention (drug or device), specific indication (disease or condition), or general therapeutic area.

| 31 Results

Title
Intervention Indication Therapeutic Area Year Actions
Veliparib in Combination with Carboplatin and Paclitaxel for Breast Cancer – First to Third Line Carboplatin (Paraplatin) , Paclitaxel (Taxol; paclitaxel albumin) , Veliparib (ABT-888; NSC 737664) Breast cancer Breast Cancer 2017 View  |  Download
Tucatinib in addition to trastuzumab and capecitabine for advanced breast cancer Capecitabine (Xeloda) , Trastuzumab (Herceptin; RG-597) , Tucatinib (ONT-380) Breast cancer Breast Cancer 2020 View  |  Download
Trastuzumab emtansine in combination with pertuzumab for HER2-positive early breast cancer - adjuvant therapy Pertuzumab (Perjeta; R-1273) , Trastuzumab Emtansine (Kadcyla; T-DM1; PRO132365) Breast cancer Breast Cancer 2019 View  |  Download
Trastuzumab Emtansine for HER2-positive breast cancer - adjuvant Trastuzumab Emtansine (Kadcyla; T-DM1; PRO132365) Breast cancer Breast Cancer 2018 View  |  Download
Trastuzumab deruxtecan for unresectable or metastatic HER2-low (HR+/-) breast cancer – after chemotherapy Trastuzumab deruxtecan (DS-8201a; Enhertu) Breast cancer Breast Cancer 2021 View  |  Download
Trastuzumab deruxtecan for metastatic HER2 - positive breast cancer – second line Trastuzumab deruxtecan (DS-8201a; Enhertu) Breast cancer Breast Cancer 2020 View  |  Download
Trastuzumab deruxtecan for HER2-positive metastatic or unresectable breast cancer Trastuzumab deruxtecan (DS-8201a; Enhertu) Breast cancer Breast Cancer 2019 View  |  Download
Taselisib in Combination with Fulvestrant for Advanced ER Positive, HER2-negative Breast Cancer – Second Line After Aromatase Inhibitor Therapy Fulvestrant (Faslodex) , Taselisib (GDC-0032; RG-7604) Breast cancer Breast Cancer 2017 View  |  Download
Sacituzumab govitecan for treating HR+/HER2- negative metastatic breast cancer Sacituzumab Govitecan (IMMU-132; Trodelvy) Breast cancer Breast Cancer 2021 View  |  Download
Sacituzumab govitecan for metastatic or unresectable locally advanced triple-negative breast cancer – third line Sacituzumab Govitecan (IMMU-132; Trodelvy) Breast cancer Breast Cancer 2021 View  |  Download
1 2 3 4
Medicines
Medicine Industry's Gateway to NICE
Support for Industry
Outputs & Publications